SOHO Annual Meeting

Real-World Data Show Tisagenlecleucel is an Effective Treatment for DLBCL

September 15, 2019

In a prospective postmarketing assessment, the use of tisagenlecleucel for treatment of adult patients with diffuse large B-cell lymphoma, lead to responses that were similar to studies of children and adolescents with B-cell acute lymphoblastic leukemia.

More Research and Development on JAK Inhibition May Improve Myelofibrosis Management

September 15, 2019

In an interview with Targeted Oncology during the 2019 SOHO Annual Meeting, Laura C. Michaelis, MD, discussed the currently approved JAK inhibitors and the future landscape for myelofibrosis, as well as treatment considerations for graft-versus-host disease.

Safety Profiles of Ruxolitinib and Fedratinib in Myelofibrosis

September 14, 2019

Prithviraj Bose, MD, discusses differences in the safety profiles of ruxolitinib and fedratinib in the treatment of myelofibrosis.

Phase II JULIET Study Continues To Show Benefit of Tisagenlecleucel in DLBCL

September 14, 2019

Recent updates to the JULIET study, presented at the 2019 SOHO Annual Meeting, show that tisagenlecleucel has sustained benefit throughout the course of the trial with high response rates, and long duration in adults with relapsed/refractory diffuse large B-cell lymphoma.

Improvement in PFS Shown With Checkpoint Inhibition Before Transplantation in R/R Hodgkin Lymphoma

September 13, 2019

In a retrospective study of patients with replaced or refractory Hodgkin lymphoma, checkpoint inhibition prior to haploidentical stem cell transplantation improved progression-free survival and risk for relapse, based on results presented at the 2019 SOHO Annual Meeting.

Fedratinib Approval Further Validates JAK Inhibition for Myelofibrosis Treatment

September 13, 2019

In an interview with Targeted Oncology during the 2019 SOHO Annual Meeting, Ruben Mesa, MD, discussed the JAKARTA and JAKARTA-2 studies and the implications their data have on the field of myelofibrosis.

Ruxolitinib Used to Prevent GVHD Throughout Stem Cell Transplantation

September 13, 2019

David S. Snyder, MD, discusses using ruxolitinib to prevent patients receiving stem cell transplantation from developing graft versus host disease.

Pemmaraju Reviews Potential Combination Regimens With Ruxolitinib for Myelofibrosis

September 13, 2019

Naveen Pemmaraju, MD, discussed potential combination regimens with ruxolitinib (Jakafi) being explored to improve outcomes for patients with myelofibrosis at the 2019 SOHO Annual Meeting.

Expert Suggests Novel Approaches To Improve CAR Therapies in ALL

September 13, 2019

To improve the efficacy of chimeric antigen receptor T-cell therapies, Nirali N. Shah, MD, MHSc, suggested including new constructs that target more than 1 antigen in patients with acute lymphoblastic leukemia, during a presentation at the 2019 SOHO Annual Meeting.

Dose Modifications to Duvelisib Do Not Compromise Outcomes in R/R CLL/SLL

September 12, 2019

Two analyses of the phase II DUO trial show that modifying the dosage of duvelisib or interrupting treatment in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, does not compromise outcomes or increase toxicity.